查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2022527

頭頸部鱗狀細胞癌（HNSCC）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 153 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 法國頭頸部鱗狀細胞癌市場預計將從 2025 年的 1.05 億美元成長到 2035 年的 3.35 億美元，這反映了在免疫療法日益普及的推動下，該市場實現了強勁的兩位數成長。
  • 市場擴張受以下因素支撐：
  • 免疫查核點抑制劑（PD-1抑制劑）的廣泛應用
  • 晚期疾病中聯合治療的廣泛應用
  • 雖然患者數量相對穩定成長，但市場規模的成長主要受癌症藥物高昂成本和治療時間延長的影響。
  • 未來的成長取決於免疫腫瘤學、標靶治療和旨在提高存活率的個人化治療策略的進步。

頭頸部鱗狀細胞癌（HNSCC）概述

頭頸部鱗狀細胞癌（HNSCC）是一組生物學異質性強、侵襲性高的惡性腫瘤，發生於口腔、咽喉和喉部的黏膜上皮。它是全球最常見的癌症之一，其主要原因是長期接觸菸草和酒精，以及感染高危險型人類乳突病毒（HPV）。

HPV陽性頭頸部鱗狀細胞癌（HNSCC），尤其是口咽癌，常伴隨晚期淋巴結轉移，與HPV陰性病例相比，預後較好，治療反應較高，逐漸形成獨特的臨床亞型。大多數患者確診時已處於局部晚期，需要多學科綜合治療以盡可能保留功能，包括手術、放射線治療和含鉑類藥物類放射線治療合併放療。然而，復發率仍然很高，相當一部分患者會發展為復發/轉移性疾病（R/M）。

隨著PD-1標靶免疫查核點抑制劑的引入，復發/轉移性頭頸部鱗狀細胞癌（R/M HNSCC）的治療模式發生了顯著變化。這些藥物構成了治療的基礎，既可作為單一藥物治療，也可與化療聯合治療。儘管取得了這些進展，但整體預後仍然較差，凸顯了開發更有效、更持久的治療策略的必要性。

主要亮點

  • 在美國，預期盛行率（經存活已調整的病例）將從 2025 年的 404,100 例增加到 2035 年的 432,300 例，呈穩定成長趨勢（年複合成長率為 0.7%）。
  • 高復發率和進展為轉移性疾病仍然是主要的臨床挑戰，晚期的長期存活率有限。
  • 免疫療法和基於生物標記的治療方法的日益普及，正在極大地改變治療格局，尤其是在復發和轉移的情況下。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准和順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Fulgent Pharma LLC.
  • CSPC Megalith Biopharmaceutical Co., Ltd.
  • Gilead Sciences
  • Merck Sharp &Dohme LLC
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Transgene
  • Regeneron Pharmaceuticals
  • Inhibrx Biosciences, Inc
  • AstraZeneca
  • Coherus Oncology, Inc.
  • Ipsen
  • Radiopharm Theranostics, Ltd
  • KaliVir Immunotherapeutics
  • IDEAYA Biosciences
  • ImmunityBio, Inc.
  • Rondo Therapeutics
  • AbbVie
  • Sutro Biopharma, Inc.
  • SystImmune Inc.
  • Zumutor Biologics Inc.
  • Arcus Biosciences, Inc.
  • Normunity AccelCo, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
  • 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興治療方法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook

Thelansis's "Head and Neck Squamous Cell Carcinoma (HNSCC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Head and Neck Squamous Cell Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) is a biologically heterogeneous and highly aggressive group of malignancies arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It represents one of the most prevalent cancers globally and is driven by two primary etiological pathways: chronic exposure to tobacco and alcohol, and infection with high-risk human papillomavirus (HPV).

HPV-positive HNSCC, particularly in the oropharynx, has emerged as a distinct clinical subtype with improved prognosis and greater responsiveness to treatment compared to HPV-negative disease, despite often presenting with advanced nodal involvement. Most patients are diagnosed at a locally advanced stage, requiring multidisciplinary, function-preserving treatment approaches, including surgery, radiation therapy, and platinum-based chemoradiation. However, recurrence rates remain high, with a significant proportion progressing to recurrent or metastatic (R/M) disease.

The treatment paradigm for R/M HNSCC has evolved significantly with the introduction of immune checkpoint inhibitors targeting PD-1, which have become a cornerstone of therapy, either as monotherapy or in combination with chemotherapy. Despite these advances, overall prognosis remains poor, highlighting the need for more effective and durable treatment strategies.

Key Highlights

  • In the US, prevalence (survival-adjusted cases) is projected to increase from 404.1K in 2025 to 432.3K by 2035, reflecting steady growth (0.7% CAGR).
  • High rates of recurrence and progression to metastatic disease remain a major clinical challenge, with limited long-term survival in advanced stages.
  • Increasing adoption of immunotherapy and biomarker-driven treatment approaches is reshaping the therapeutic landscape, particularly in recurrent/metastatic settings.

Market Overview

  • The France HNSCC market is projected to grow from $105M in 2025 to $335M by 2035, reflecting strong double-digit growth driven by expanding use of immunotherapies.
  • Market expansion is supported by:
  • Increased uptake of immune checkpoint inhibitors (PD-1 inhibitors)
  • Broader use of combination regimens in advanced disease
  • Despite relatively stable patient growth, market value is driven by high-cost oncology therapies and extended treatment duration.
  • Future growth will depend on advancements in immuno-oncology, targeted therapies, and personalized treatment strategies to improve survival outcomes.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Fulgent Pharma LLC.
  • CSPC Megalith Biopharmaceutical Co., Ltd.
  • Gilead Sciences
  • Merck Sharp & Dohme LLC
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • Transgene
  • Regeneron Pharmaceuticals
  • Inhibrx Biosciences, Inc
  • AstraZeneca
  • Coherus Oncology, Inc.
  • Ipsen
  • Radiopharm Theranostics, Ltd
  • KaliVir Immunotherapeutics
  • IDEAYA Biosciences
  • ImmunityBio, Inc.
  • Rondo Therapeutics
  • AbbVie
  • Sutro Biopharma, Inc.
  • SystImmune Inc.
  • Zumutor Biologics Inc.
  • Arcus Biosciences, Inc.
  • Normunity AccelCo, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)